Optimal use of recombinant factor VIIa in the control of bleeding episodes in hemophilic patients

Drug Design, Development and Therapy

Volumn 4, Issue , 2010, Pages 127-137

  Puetz, John ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Factor VIIa; Hemophilia; Inhibitor; Inhibitors; Recombinant

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A; ALLOANTIBODY; AUTOANTIBODY; HEMOSTATIC AGENT; RECOMBINANT FVIIA; RECOMBINANT PROTEIN;

BLEEDING; BLOOD CLOTTING FACTOR 7 DEFICIENCY; BOLUS INJECTION; COMPASSIONATE USE; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG ACCUMULATION; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; GLANZMANN DISEASE; HEMARTHROSIS; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; MUSCLE BLEEDING; NONHUMAN; OFF LABEL DRUG USE; ORAL BLEEDING; PHLEBITIS; POSTOPERATIVE HEMORRHAGE; PROPHYLAXIS; REVIEW; SINGLE DRUG DOSE; THROMBOCYTE DISORDER; THROMBOEMBOLISM; THROMBOPHILIA; THROMBOPHLEBITIS; UNSPECIFIED SIDE EFFECT; HALF LIFE TIME; IMMUNOLOGY; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC);

AUTOANTIBODIES; FACTOR VIIA; HALF-LIFE; HEMOPHILIA A; HEMOSTATICS; HUMANS; ISOANTIBODIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT PROTEINS;

EID: 79952027001     PISSN: 11778881     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Manco-Johnson M, Abshire T, Shapiro A, et al. Prophylactic versus episodic treatment to prevent joint disease in boys with severe hemophilia. New Engl J Med. 2007;357:535-544.
2. Hoyer L. Hemophilia A. N Engl J Med. 1994;330(1):38-47.
3. Valentino L, Veeral M. Blood safety and the choice of anti-hemophilic factor concentrate. Pediatr Blood Cancer. 2006;47:245-254.
4. Ettingshausen C, Kreuz W. Role of von Willebrand factor in immune tolerance induction. Blood Coag Fibrinolysis. 2005;16 Suppl 1: S27-S31.
5. Gouw S, Van Den Berg H, Le Cessie S, Van Den Bom J. Treatment characteristics and the risk of inhibitor development: A multicenter cohort study among previously untreated patients with severe hemophilia A. J Thromb Haemost. 2007;5:1383-1390.
6. DiMichele D, Kroner B. The North American Immune Tolerance Registry: Practices, outcomes, outcome predictions. Thromb Haemost. 2002;87:52-57.
7. Hay C, Negrier C, Ludlam C. The treatment of bleeding in acquired haemophilia with recombinant factor VIIa: A multicentre study. Thromb Haemost. 1997;79:1463-1467.
8. Roberts H, Monroe D, White G. The use of recombinant factor VIIa in the treatment of bleeding disorders. Blood. 2004;104:3858-3864.
9. Butenas S, Brummel K, Branda R, Paradis S, Mann K. Mechanism of factor VIIa-dependent coagulation in hemophilia blood. Blood. 2002;99: 923-930.
10. Fay P. Factor VIII structure and function. Internat J Hematol. 2006;83: 103-108.
11. Hedner U. factor VIIa in the treatment of haemophilia. Blood Coagul Fibrinolysis. 1990;1:303-317.
12. Hedner U. Recombinant coagulation factor VIIa: From the concept to clinical application in hemophilia treatment 2000. Seminars Thromb Hemost. 2000;26:363-366.
13. Hedner U, Kisiel W. Use of human factor VIIa in the treatment of two hemophilia A patients with high titer inhibitors. J Clin Invest. 1983;71: 1836-1841.
14. Kisiel W. Recollections of the discovery of factor VIIa as a novel therapeutic agent for hemophiliacs with inhibitors. J Thromb Haemost. 2009;7:1053-1056.
15. Hoffman M, Monroe D, Roberts H. Activated factor VII activates factors IX and X on the surface of activated platelets: Thought on the mechanism of action of high-dose activated factor VII. Blood Coagul Fibrinolysis. 1998;9 Suppl 1:S61-S65.
16. Persson E, Bolt G, Steenstrup T, Ezban M. Recombinant coagulation factor VIIa - from molecular to clinical aspects of a versatile haemostatic agent. Thromb Res. 2009 Dec 16. [Epub ahead of print].
17. Brinkhouse K, Hedner U, Garris J, Diness V, Read M. Effect of recombinant factor VIIa on the hemostatic defect in dogs with hemophilia A, hemophilia B, and von Willebrand disease. Proc Natl Acad Sci U S A. 1989;86:1382-1386.
18. Erhardtsen E. Pharmacokinetics of recombinant activated factor VII (rFVIIa). Seminars Thromb Hemost. 2000;26:385-391.
19. Lindley C, Sawyer W, Macik G, et al. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa. Clin Pharmacol Ther. 1994;55: 638-648.
20. Gopalakrishnan R, Hedner U, Ghosh S, et al. Bio-distribution of pharmacologically administered recombinant factor VIIa (rFVIIa). J Thromb Haemost. 2010;8:301-310.
21. Hedner U, Schulman S, Alberts K, et al. Successful use of rFVIIa in a patient with severe hemophilia subjected to synovectomy. Lancet. 1988;2:1193.
22. Lusher J, Roberts H, Davignon G, et al. A randomized, double blind comparison of two dosage levels of recombinant factor VIIa in the treatment of joint, muscle and mucocutaneous haemorrhages in persons with haemophilia A and B, with and without inhibitors. Haemophilia. 1998;4:790-798.
23. Key N, Aledort L, Beardsley D, et al. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost. 1998;80:912-918.
24. Shapiro A, Gilchrist G, Hoots K, Cooper H, Gastineau D. Prospective, randomized trial of two doses of rFVIIa (Novoseven) in haemophilia patients with inhibitors undergoing surgery. Thromb Haemost. 1998; 80:773-778.
25. Bysted B, Schurling B, Moller T, Hansen B. A randomized, double-blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C formulation. Haemophilia. 2007;13:527-532.
26. Astermark J, Dorfield S, DiMichele D, et al. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: The FEIBA Novoseven Comparitive (FENOC) study. Blood. 2007;109:546-551.
27. Gringeri A, Santagostino E, Mannucci P. Failure of recombinant activated factor VII during surgery in a hemophiliac with high-titer factor VIII antibody. Haemostasis. 1991;21:1-4.
28. Schulman S, Bech Jensen M, Varon D, et al. Feasibility of using recombinant factor VIIa in continuous infusion. Thromb Haemost. 1996;75: 432-436.
29. Schulman S; for the rFVIIa CI group. Continuous infusions of recombinant factor VIIa in hemophilic patients with inhibitors: Safety, monitoring, and cost effectiveness. Sem Thromb Hemost. 2000;26:421-424.
30. Chuansumrit A, Isarangkura P, Angchaisuksiri P, et al. Controlling acute bleeding episodes with recombinant factor VIIa in haemophiliacs with inhibitor: Continuous infusions and bolus injection. Haemophilia. 2000;6:61-65.
31. Bonde C, Bech Jenses M. Continuous infusion of recombinant activated factor VII: Stability in infusion pump systems. Blood Coagul Fibrinolysis. 1998;9 Suppl 1:S103-S105.
32. Shapiro A. Inhibitor treatment: State of the art. Semin Hematol. 2001;38 Suppl 12:26-34.
33. Mauser-Bunschoten E, Koopman M, Goede-Bolder A, et al. Efficacy of recombinant factor VIIa administered by continuous infusion to hemophilia patients with inhibitors. Haemophilia. 2002;8:649-656.
34. Smith M, Ludlum C, Collins P, et al. Elective surgery of factor VIII inhibitor patients using continuous infusion of recombinant activated factor VII. Thromb Haemost. 2001;86:949-953.
35. Kenet G, Lubetsky A, Luboshitz J, Martinowitz U. A new approach to treatment of bleeding episodes in young hemophilia patients: A single bolus megadose of recombinant activated factor VII (Novoseven). J Thromb Haemost. 2003:1:450-455.
36. Pruthi R, Mathew P, Valentino L. Haemostatic efficacy and safety of bolus and continuous infusions of recombinant factor VIIa are comparable in haemophilia patients with inhibitors undergoing major surgery. Thromb Haemost. 2007;98:726-732.
37. Ludlan C, Smith M, Morfini M, et al. A prospective study of recombinant activated factor VII administered by continuous infusion to inhibitor patients undergoing elective major orthopaedic surgery: A pharmacokinetic and efficacy evaluation. Br J Haematol. 2003;120: 808-813.
38. Kjalke M, Ezban M, Monroe D, et al. High dose factor VIIa increases initial thrombin generation and modulated faster platelet activation in a thrombocytopenic-like condition in a cell based model system. Br J Haemat. 2001;114:114-120.
39. Parameswaran R, Shapiro A, Gill J, Kessler C. and HTRS Registry. Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: Analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia. 2005;11:100-106.
40. Chuansumrit A, Sri-Udompora N, Srimuninnimit V, Juntarukha R. A single high dose or recombinant factor VIIa combining adjuvant therapy for controlling bleeding episodes on haemophiliacs with inhibitors. Haemophilia. 2001;7:532-536.
41. Santagostino E, Mancuso M, Rocino A, et al. A prospective randomized trial of high and standard dosages of recombinant factor VIIa for treatment of hemarthrosis in hemophiliacs with inhibitors. J Thromb Haemost. 2006;4:367-371.
42. Kavakli K, Makris M, Zulfikar B, et al. Home treatment of haemorrhages using a single dose regimen of recombinant activated factor VII in patients with haemophilia and inhibitors. Thromb Haemost. 2006;95:600-605.
43. Young G, Shafer F, Rojas P, Seremetis S. Single 270 mcg kg-1 dose rFVIIa vs standard 90 mcg kg-1 dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: A randomized comparison. Haemophilia. 2008;14:287-294.
44. Goldstein B, Geldziler B, Bjerre J, Seremetis S. Evidence based use of recombinant FVIIa (Novoseven, Niastase) for the treatment of hemophilia with inhibitors in children and adolescents. Transfusion and Apheresis Science. 2008;38:25-32.
45. Feldman B, Pai M, Rivard G, et al. Tailored prophylaxis in severe hemophilia A: Interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2006;4: 1228-1236.
46. Young G, McDaniel M, Nugent D. Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors. Haemophilia. 2005;11: 203-207.
47. Jiminez-Yuste V, Alvarez M, Martin-Salces M, et al. Prophylaxis in 10 patients with severe haemophilia A and inhibitor: Different approaches for different clinical situations. Haemophilia. 2009;15:203-209.
48. Jiminez-Yuste V, Quintana M, Alvarez M, Martin Salces M, Hernandez-Navarro F. Primary prophylaxis with rFVIIa in a patient with severe haemophilia A and inhibitor. Blood Coagul Fibrinolysis. 2008;19:719-720.
49. Morfini M, Auerswald G, Kobelt A, et al. Prophylactic treatment of haemophilia patients with inhibitors: Clinical experience with recombinant factor VIIa in European Haemophilia Centres. Haemophilia. 2007;13:502-507.
50. Konkle B, Ebbesen L, Erhardtsen E, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5: 1904-1913.
51. Hoots K, Ebbesen S, Konkle B, et al. Secondary prophylaxis with recombinant activated factor VII improves health related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008;14:466-475.
52. Aledort L. Comparative thromboembolic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004;2:1700-1708.
53. O'Connell K, Wood J, Wise R, Lozier J, Braun M. Thromboembolic adverse events after use of recombinant human coagulation factor VIIa. JAMA. 2006;295:293-298.
54. Abshire T, Kenet G. Recombinant factor VIIa: Review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VIII or IX inhibitors. J Thromb Haemost. 2004;2:899-909.
55. Abshire T, Kenet G. Safety update on the use of recombinant factor VIIa and the treatment of congenital and acquired deficiencies of factor VIII or IX with inhibitors. Haemophilia. 2008;14:898-902.
56. Puetz J, Darling G, Brabec P, Blatny J, Matthew P. Thrombotic events in neonates receiving recombinant factor VIIa or fresh frozen plasma. Pediatr Blood Cancer. 2009;53:1074-1078.
57. Bromken C, Mathai S, Biss T, Loughney A, Hanley J. Recombinant activated factor VII (rFVIIa) in the management of major obstetric haemorrhage: A case series and proposed guideline for use. Obstet Gynecol Int. 2010. [Epub Feb 3].
58. Hoots W. Challenges in the therapeutic use of a "so called" universal hemostatic agent: Recombinant factor VIIa. Hematology 2006. The American Society of Hematology Education Program Book. 426-431.
59. Vincent J, Rossaint R, Riou B, Ozier Y, Zideman D, Spahn D. Recommendations on the use of recombinant activated factor VII as an adjunctive treatment for massive bleeding - a European perspective. Crit Care. 2006;10:R120.
60. Johansson P. Off-label use of recombinant factor VIIa for treatment of haemorrhage: Results from randomized clinical trials. Vox Sang. 2008;95:1-7.
61. Hsia C, Chin-Yee I, Mcalister V. Use of recombinant activated factor VII in patients without hemophilia. A meta-analysis of randomized control trials. Ann Surg. 2008;248:61-68.
62. Moss J, Scharling B, Ezban M, Moller Sorensen T. Evaluation of the safety and pharmacokinetics of a fast-acting recombinant FVIIa analogue, NN1731, in healthy male subjects. J Thromb Haemost. 2009;7:299-305.
63. Schulte S. Use of albumin fusion technology to prolong the half-life of recombinant factor VIIa. Thromb Res. 2008;122 Suppl 4:S14-S19.
64. Yatuv R, Dayan I, Carmel-Goren L, et al. Enhancement of factor VIIa haemostatic efficacy by formulation with PEGylated liposomes. Haemophilia. 2008;14:476-483.